Meanwhile, the three largest and most recent studies [5, 7, 15] observed that KIT mutations should be considered as an entity, not in genotypes, for the prognostic effect in CBF-AML, which must be determined in further high-quality studies. This evidence concerns the gene KIT and acute myeloid leukemia.